2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - New Orleans Theatre B
Technology and Procedures, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Vaccines, Immunotherapy, Monoclonal Antibody Therapy, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, T Cell Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human
PAPER

908 High complete response rates, durable CD5-negative T-cell persistence, and mechanistically tractable delayed immune-mediated toxicity after low-dose CD5-edited CD5 CAR T-cell therapy in relapsed/refractory T-cell lymphoma

Stefan K Barta, MD, Ran Reshef, MD, MSc2, Stephen J Schuster, MD3, Luca Paruzzo, MD4, Alberto Carturan, MD5, Colin J. Thomas, MD6, Jakub Svoboda, MD7, Jordan S Carter, MD8, Sunita Dwivedy Nasta, MD, MS9, Daniel Landsburg, MD10, Pooja Devi, MD11, Elise A. Chong, MD12, Ruchi Patel, PhD13, Joseph Fraietta, PhD14, Omar Elghawy, MD15, Aditya Nimmagadda16, Lavanya Peddada17, Adam Snook, PhD18, Nicholas A Siciliano, PhD19, Rosemary Mazanet, MD PhD20, Marco Ruella, MD21
1 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
2 Columbia University Irving Medical Center, New York, New York, United States
3 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
8 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
10 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
11 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
13 University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
16 Vittoria Biotherapeutics, Philadelphia, Pennsylvania, United States
17 Vittoria Biotherapeutics, Philadelphia, Pennsylvania, United States
18 Vittoria Biotherapeutics, Philadelphia, Pennsylvania, United States
19 Vittoria Biotherapeutics, Philadelphia, Pennsylvania, United States
20 Vittoria Biotherapeutics, Philadelphia, Pennsylvania, United States
21 University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States, University of Pennsylvania, Philadelphia, Pennsylvania, United States

Background
Relapsed or refractory (r/r) T-cell lymphomas carry a poor prognosis and few therapeutic options. Chimeric antigen receptor (CAR) T-cell therapy has transformed patient outcomes in B-cell malignancies, but translation to T-cell malignancies is challenged by fratricide and on-target T-cell aplasia. Senza5 CART5 is a rapidly manufactured (5-day) autologous CD5-edited product containing CD5⁻CAR⁺ cells for antitumor activity and companion CD5⁻CAR⁻ cells designed to resist on-target pressure and support immune reconstitution. In the ongoing phase 1 VIPER-101 trial (NCT06420089), we characterized manufacturing, expansion, persistence, immune reconstitution, tissue trafficking, and mechanisms of toxicity.

Methods
Adults with r/r T-cell lymphoma after ≥1 prior therapy received lymphodepletion and a single Senza5 CART5 infusion in this open-label, dose-finding phase 1 trial. Manufacturing data derived from product-release testing. CAR T-cell expansion, persistence, and tissue trafficking were assessed by targeted quantitative PCR (qPCR); peripheral T-cell populations and serum cytokines (32-plex Luminex) were profiled longitudinally.

Results
As of June 30, 2026, 8 pts (3 AITL, 2 PTCL-NOS, 2 MF, 1 nodal TFHL) were treated: 7 at 3 × 10⁶ CAR⁺ cells (DL-1) and 1 at 1 × 10⁷ (DL1). Median age was 67.5 years (range, 56-74); 7 of 8 pts were male; race/ethnicity was White 4, Black 2, Asian 1, Hispanic/Latino 1. Pts had received a median of 3 prior regimens (range, 2-5); one had a prior autologous stem cell transplant. Manufacturing success was 100% (8/8); all products met the assigned dose level, with CD5 knockout ≥90% and CAR⁺ cells a median 28% of the product (range, 16-42%).

The best overall response rate was 88% (7/8) and complete response (CR) rate 75% (6/8); 1 pt remains in CR at >9 months (median follow-up, 7.0 months) at extraordinarily low CAR+ cell doses (3-10M CAR+ cells/patient). CRS occurred in all 8 pts but was limited to grade 1-2; no ICANS and no dose-limiting toxicities were observed. Distinctive delayed treatment-related adverse events (TRAEs) occurred: grade 1-2 xerostomia (7/8), grade 1-2 maculopapular rash (3/8), late ICAHT (3/8), and grade 3 IEC-associated enterocolitis (1/8). Two patient deaths were associated with infection, one with EBV+ B-cell lymphoma, one with progressive disease, and one with relapsed disease. The observed TRAEs resembled delayed CAR T immune-related adverse events (CirAE) prompting analysis of CAR T cell and cytokine dynamics.

All pts had robust CART expansion (median peak 32,239 copies/µg gDNA; range, 3,391-91,151), peaking at a median of day 14 (range, 14-35). The single non-responder was the only pt to receive bendamustine lymphodepletion, and experienced blunted expansion kinetics. Trafficking to disease sites (lymph node, skin, marrow) was detected in all evaluable pts, in whom CAR⁺ cells persisted beyond month 1 and remained detectable at last follow-up (median 508 copies/µg gDNA; range, 95-14,165), documented through month 9.

Longitudinal immune profiling demonstrated depletion of endogenous CD5⁺CAR⁻ T cells beginning on day 12, in parallel with CAR⁺ T-cell expansion, and sustained reconstitution by CD5⁻CAR⁻ T cells which became the predominant circulating T-cell population and persisted for the duration of follow-up.

Among 5 evaluable pts with TRAEs, affected tissues showed Senza5 CART5 infiltration by qPCR (range, 2,823-20,917 copies/µg gDNA) or dense CD5⁻ T-cell infiltration with CD4 skewing, suggesting localized immune phenomena.

Serum cytokine profiling revealed a coordinated peak in inflammatory cytokines (IL-6, IL-8, CXCL10, TNF-α) together with the lymphopoietic cytokine IL-7, between days 10 and 14. This temporal pattern paralleled the CART-cell expansion kinetics.

Conclusions
Senza5 CART5 demonstrated high antitumor activity, robust expansion, durable persistence, and sustained CD5-negative immune reconstitution at exceptionally low CAR⁺ cell doses. CRS was limited to grade 1-2 with no ICANS or dose-limiting toxicities. Delayed toxicities were tissue-localized and clinically resemble the delayed CirAE that have been described after BCMA-directed CAR T, informing the management of these side effects. These data support continued development of Senza5 CART5 and resulted in FDA Orphan Drug designation. Furthermore, evaluation of CD5 abrogation is a promising new approach to enhance engineered T cells for additional indications. 

Stefan K Barta, MD: Acrotech - Honoraria; Kyowa Kirin - Honoraria; Biovent - Honoraria; Kymera - Research Funding; Ono Pharmaceutical - Research Funding; Biovent - Research Funding; Vittoria Biotherapeutics - Research Funding; Affimed - Research Funding; Kyowa Kirin - Research Funding; Citius - Consultancy (Includes expert testimony); Kyowa Kirin - Consultancy (Includes expert testimony); Acrotech - Consultancy (Includes expert testimony); Secura Bio - Consultancy (Includes expert testimony)